LIMN Liminatus Pharma, Inc. Class A Common Stock
Healthcare$0.16-3.25%ClosedMarket Cap: $4.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-30.35
P/S
0.00
EV/EBITDA
-0.38
DCF Value
$-0.05
FCF Yield
-263.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
215.7%
ROA
-394.3%
ROIC
-283.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-1.1M | $-1.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-884.2K | $-8.2M | $— | — |
| FY null | $0.00 | NaN% | $-3.0M | $-10.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-701.2K | $-1.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-1.1M | $113.3K | $— | — |
| Q1 null | $0.00 | NaN% | $-255.00 | $-255.00 | $— | — |
| Q4 null | $0.00 | NaN% | $-522.8K | $-868.3K | $— | — |
| FY null | $0.00 | NaN% | $-2.9M | $-2.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.0M | $-642.9K | $— | — |
| Q2 null | $0.00 | NaN% | $-642.1K | $-534.9K | $— | — |
| Q1 null | $0.00 | NaN% | $-1.7M | $-1.8M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-642.7K | $-486.6K | $-0.07 | — |